In targeting DNA repair pathways of the most genomic instable cancer, poly-(adenosine diphosphate [ADP])-ribose polymerase inhibitors (PARPi) have been demonstrated as the most effective drug since platinum in high grade serous or endometrioid ovarian cancer. Immunotherapy is strongly pushing the door of ovarian cancer and has the ambition to change the fate of this deadly disease when combined with chemotherapy, vascular endothelial growth factor inhibitor or PARPi. The activity of PARPi could also be improved by modulators of the cell cycle, which are required to give time enough for DNA repair. Even more ambitious are drug targeting the driver p53 mutation or the pathway which inhibit tumor cell apoptosis. Some original approaches still give life to new chemotherapy compounds such as the marine derivative lurbinectedin or the immunoconjugate mirvetuximab soravtansine including a monoclonal antibody targeting the folate receptor.
Introduction
Poly-(adenosine diphosphate [ADP])-ribose polymerase inhibitors (PARPi) are on the way to transform the epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC) patient outcome. Olaparib, the first in class is still the only one being approved in European Union. However, related compounds such as rucaparib or niraparib are approved in the United States together with olaparib and are looking for finding their place. DNA damage repair targeted drugs, however, are not limited to PARPi which target the homologous recombination repair (HRR) pathway. Modulators of the cell cycle are aimed at preventing cycle arrest required for DNA repair and have recently opened the door in ovarian cancer. Among other drugs of potential interest are those which target mutant p53, the folate receptor alpha, the inhibitors of apoptose proteins (IAPs) and the trabectedin derivative lurbinectedin. The list would not be complete if immunotherapy was not pointed out as one of the most promising field for future advances in EOC.
DNA damage repair targeted drugs
DNA repair targeted therapies exploit DNA repair defects in cancer cells to generate synthetic lethality (e.g. cancer cells defective in one DNA repair pathway rely on alternate repair pathways; inhibition of a second repair pathway then results in cell death), an effect which selectively targets repair-deficient cancer cells.
PARP inhibitors
Approximately 50% of epithelial high grade serous ovarian carcinomas (HGSOC) are expected to exhibit dysfunctional HRR. HRR deficiency confers sensitivity to inhibitors of the PARP enzyme, which is vital to several DNA repair pathways, including base excision repair and nonhomologous end-joining pathways.
Olaparib is the first approved PARPi in EOC. In European Union, olaparib is approved in platinum-sensitive relapse as a maintenance treatment after responding to platinum-based chemotherapy in patients with HGSOC and a germline and/or somatic BRCA mutation. This label was based on study 19, which showed that olaparib as capsule benefited to all comers HGSOC patients with a progression-free survival (PFS) hazard ratio (HR) of 0.35 compared to placebo. The benefit was greater in patients with a germline or somatic BRCA1/2 mutation (HR ¼ 0.18) [1] .
The activity of olaparib as maintenance in late relapse (platinum-free interval > 6 months) [2] was beautifully confirmed by the randomized phase III Study of OLaparib in Ovarian cancer (SOLO2) trial recently reported [3] . In this study, patients with high-grade serous or endometrioid OC and a BRCA1/2 mutation who were treated with olaparib as tablets (4 tablet/day versus 16 capsules/day) enjoyed a significant prolongation of their median progression-free survival (19.1 versus 5.5 months, HR ¼ 0.30). Secondary end points such as time to first or second subsequent treatment were also prolonged. Interestingly enough, despite a higher frequency of digestive symptoms such as nausea and increased asthenia correlated to anemia occurrence for patients treated with olaparib, global quality of life was not significantly altered. In contrast, the time without symptom or toxicity was significantly prolonged in the olaparib arm [4] .
The Niraparib in OVArian cancer (NOVA) study evaluated the efficacy and tolerance of niraparib in the same setting of maintenance therapy after response to platinum chemotherapy in late relapse, but in all comers with high grade serous or endometrioid OC [5] . This phase III study confirmed globally the results of the randomized phase II study 19 with olaparib, giving more evidence to the critical role of PARPi in patients with ovarian cancer relapse. Again, in the BRCA mutated population was observed a striking PFS prolongation (21.0 versus 5.5 months, HR ¼ 0.27), which was very similar to that observed in the SOLO2 study. Niraparib showed a tolerable toxicity profile despite an increased rate of bone marrow toxicity and dose reduction compared to olaparib. In patients without BRCA mutation, the NOVA trial explored the role of an HRD test (MyChoice from MYRIAD) in an attempt to identify the patients who are prone to respond to niraparib. However, a significant proportion of patients with negative HRD test still benefited from the drug (median PFS: 6.9 versus 3.8 months, HR ¼ 0.58). Niraparib has obtained an US label and is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
A third PARPi, rucaparib, was also tested as maintenance for patients who responded to platinum-based chemotherapy in late relapse through the phase III Assessment of Rucaparib in Ovarian cancer: Phase 3 trial (ARIEL3). The preliminary results of this study were disclosed through a press release on 06/19/2017 and showed efficacy results comparable to olaparib and niraparib [6] .
PARPi can also be used instead of chemotherapy as treatment of ovarian cancer relapse for patients with BRCA1 or BRCA2 mutation. In United States, olaparib is approved for patients with recurrent EOC who have a germline deleterious BRCA1/2 mutation and have been treated by at least three prior lines of chemotherapy and rucaparib was approved for patients who have a germline or somatic BRCA1/2 mutation and in whom at least two lines of therapy have failed, respectively [7, 8] .
What are the future directions for PAPRi in EOC? One of the future challenges is to find out what is the best combination with Platin, Avastin and OLAparib (PARPi). Preliminary efficacy results of combining olaparib and cediranib, a VEGF TKI, in late relapse were highly encouraging [9] and phase III trials are on-going to evaluate this combination both in early and late relapse (NCT02502266, NCT02446600). Perhaps more easily tolerable, the combination of niraparib and the anti-VEGF bevacizumab is also tested with the AVAstin and Niraprib in OVArian cacner (AVANOVA) randomized phase II trial in late relapse (NCT02354131). The combination of PARPi and PD1 or PD-L1 inhibitors are in early phase and their results are eagerly awaited.
The brilliant efficacy with manageable toxicity of PARPi observed in relapse prompted their evaluation in the first line. This is the case of the SOLO1 (NCT01844986) and Platin, Avastin and OLAparib in 1st line (PAOLA1) (NCT02477644) trials who have completed their accrual and are exploring the efficacy and tolerance of olaparib as first-line maintenance of advanced high-grade serous or endometrioid OC either as single drug in BRCA-mutated patients (SOLO1) or in all comers combined with bevacizumab (PAOLA1). Niraparib has also started a phase III trial as maintenance of first line (PRIMA trial, NCT02655016) in all-comers patients who have not achieved a complete resection of their high grade serous or endometrioid OC after primary surgery.
Modulators of the cell cycle
AZD1775 is a highly selective, potent, ATP competitive, small molecule inhibitor of WEE1 kinase. In vitro, AZD1775 inhibits WEE1 activity and induces DNA damage as well as G2 checkpoint escape in cell based assays. AZD1775 increases cytotoxicity when used in combination with DNA damaging agents, such as gemcitabine, cisplatin, carboplatin and topotecan, in p53-deficient cell lines. The combination of AZD1775 orally twice a day during 2.5 days every 21-day cycle with carboplatin (AUC5) achieved an impressive 43% overall response rate with a median PFS of 5.3 months in 21 evaluable patients with p53 mutant EOC in relapse less than 3 months after the last dose of platinum. The most frequent grade 3 or 4 adverse events were thrombocytopenia (48%) and neutropenia (37%) [10] .
Prexasertib (LY2606368 monomesylate monohydrate) is a small molecule that in vitro preferentially binds to and inhibits checkpoint kinase 1 (CHK1) and, to a lesser extent, inhibits checkpoint kinase 2 (CHK2), thus inducing DNA double-strand breaks, a loss in checkpoint function, increased replication stress, and cell death. In phase II, prexasertib achieves a 35% response rate (n ¼ 20) in heavily pre-treated patients without gBRCA mutation. Hematologic toxicity is also predominant [11] .
Targeting p53
APR-246 is a methylated derivative and structural analog of PRIMA-1 (p53 re-activation and induction of massive apoptosis), with potential antineoplastic activity. Upon administration, PRIMA-1 analogue APR-246 covalently modifies the core domain of mutated forms of cellular tumor antigen p53 through the alkylation of thiol groups. These modifications restore both the wild-type conformation and function of mutant p53, which reconstitutes endogenous p53 activity, leading to cell cycle arrest and apoptosis in tumor cells. This agent has been shown in vitro to work synergistically with other antineoplastic agents. A randomized phase II trial is on-going combining APR-246 with carboplatin and pegylated liposomal doxorubicin (PLD) versus carboplatin and PLD in late relapse of patients with p53 mutant EOC [P53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer (PIsARRO) trial, NCT02098343].
Ganetespib exhibits its function by competitively inhibiting the ATPase activity of the Hsp90 core protein. Due to their aberrant conformation mutp53 proteins depend on permanent folding support by the multi-component HspP90 chaperone machinery and that it is this stable interaction between mutp53 and Hsp90 that is largely responsible for mutp53 accumulation specifically in tumor cells. Hsp90 inhibition mediates effective destabilization and degradation of mutp53 in human tumor cells, acutely withdrawing an oncoprotein these cells depend on for survival. In vivo, ganetespib inhibits the growth of human tumor cell lines in mouse xenograft models. Ganetespib is currently evaluated in combination with weekly paclitaxel in women with high-grade serous, high-grade endometrioid, or undifferentiated platinum-resistant ovarian, fallopian tube or primary peritoneal cancer (Ganetespib in metastatic, p53 mutant, platinum-resistant ovarian cancer (GANNET) trial, NCT02012192).
Targeting folate receptor
Despite the setbacks of previous experiences such as those of farletuzumab and vintafolide, targeting folate receptor alpha(FR) remains an active field in OC. Mirvetuximab soravtansine (IMGN853) consists of a humanized anti-FR monoclonal antibody attached via a disulfide containing linker to the cytotoxic maytansinoid, DM4. Results from a phase I study indicate that IMGN853 elicits an overall response rate of 53% in heavily pretreated patients with platinum resistant, FR-positive EOC [12] . The majority of adverse events were grade 1 or 2 in severity and included diarrhea (44%), blurred vision (41%), nausea (37%), and fatigue (30%). FORWARD1 is currently evaluating the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus investigator's choice of chemotherapy in adults with FR-positiveplatinum resistant EOC (NCT02631876).
Targeting apoptosis
Abnormal expression of anti-apoptotic molecules is one of the most frequent mechanisms resulting in apoptosis resistance, making current anticancer therapies less effective or ineffective. Therefore, reactivation of cancer cell death programs in cancer is a promising strategy to overcome treatment resistance. IAP proteins comprise a family of anti-apoptotic proteins that promote prosurvival signalling pathways and prevent activation of the effector phase of apoptosis by interfering with the activation of caspase. Drugs targeting and inhibiting IAP proteins could be useful to induce cell death by themselves or by lowering the threshold for cell death induction when combined with other anticancer therapies like chemotherapy, targeted agents, or radiation therapy.
The small-molecule Debio 1143 is a potent orally active IAP antagonist able to promote apoptosis in tumor cells by restoring caspase activity and modulating nuclear factor-jB signaling and tumur necrosis factor-a effects. This molecule is currently tested in a randomized phase II trial of neoadjuvant carboplatin and paclitaxel, with or without Debio 1143 in patients with newly diagnosed advanced epithelial ovarian cancer.
Lurbinectedin
Lurbinectedin is a synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1 H)-one alkaloid analogue and is an inhibitor of RNA polymerase II which is essential for the transcription process that is overactivated in tumors with transcription addiction. Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.
In a two-stage controlled phase II study in 81 patients with resistant/refractory disease, lurbinectedin achieved a 23% response rate whereas no response was observed in patients treated with topotecan [13] . The CORAIL randomized phase III is currently evaluating lurbinectedin compared with PLD or topotecan in platinum-resistant disease (NCT02421588).
Immunotherapy Table 1 shows a sum-up of the molecules targeting the PD-L1/PD1 pathway. They have been tested in heavily pre-treated OC patients. Despite a high expression of PD-L1 in OC (at least on archival biopsies), the response rate remains modest, around 15%. As in other tumor types, most of these responses are long lasting.
The future of immunotherapy in OC holds in the combination of PD1/PD-L1 inhibitors with chemotherapy and/or targeted therapy. In 550 patients with early relapse, the JAVELIN200 trial (NCT02580058) compares avelumab alone versus pegylated liposomal doxorubicin (PLD) alone versus the combination of PLD þ avelumab. A similar trial is on-going exploring the combination of atezolizumab and PLD with or without bevacizumab (NCT02839707).
In 405 patients with late relapse, the ATezolizumab and Avastin in LAte recurreNT diseasE (ATALANTE) trial (NCT02891824) randomizes the combination of platinum-based chemotherapy þ bevacizumab with or without atezolizumab.
Despite the absence of data yet from these trials in relapse, immunotherapy is rapidly moving in first-line. JAVELIN100 (NCT02718417) and IMagyn050 (NCT03038100) trials are respectively testing avelumab and atezolizumab plus bevacizumab in large randomized first-line phase III studies.
Discussion Conclusion
The brilliant story of the PARPi in ovarian cancer is just starting and several trials are exploring their role beyond BRCA and in Table 1 . Drugs interacting with PD-L1/PD1pathway in ovarian cancer (from Pujade-Lauraine, ESGO 2016)
Nivolumab [14] Pembrolizumab [15] Avelumab [16] Atezolizumab [17] Durvalumab [18] 
